血小板受体作为抗血小板治疗靶点的研究进展

被引：6

作者：

舒雪梅

郭涛

机构：

[1] 华中科技大学同济医学院附属协和医院血液科

来源：

临床血液学杂志 | 2020年 / 33卷 / 01期

关键词：

抗血小板药物; 血小板受体;

D O I：

10.13201/j.issn.1004-2806.2020.01.004

中图分类号：

R96 [药理学];

学科分类号：

100602 ; 100706 ;

摘要：

<正>血小板在血栓形成过程中发挥着重要的作用。作用于血小板黏附,聚集等过程的抗血小板药物能有效地抑制体内血栓形成,预防和治疗急性冠脉综合征和缺血性脑卒中,抑制动脉粥样斑块破裂后的血栓形成,预防支架血栓形成。抗血小板治疗的作用靶点很多,本文主要对血小板上二磷酸腺苷受体,蛋白激酶受体,膜糖蛋白受体,血栓烷A2受体等受体及其拮抗剂的临床研究进展进行综述。1 血小板的功能及血小板膜受体的类型血小板的黏附、聚集、释放在动脉内血栓形成的过程中发挥

引用

页码：13 / 17

页数：5

共 15 条

[1] Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis[J] . Alexander C Fanaroff,Vic Hasselblad,Matthew T Roe,Deepak L Bhatt,Stefan K James,Ph Gabriel Steg,C Michael Gibson,E Magnus Ohman.International Journal of Cardiology . 2017
[2] New Concepts and Mechanisms of Platelet Activation Signaling
Estevez, Brian
Du, Xiaoping
[J]. PHYSIOLOGY, 2017, 32 (02) : 162 - 177
[3] The Molecular Mechanism of P2Y1 Receptor Activation
Yuan, Shuguang
Chan, H. C. Stephen
Vogel, Horst
Filipek, Slawomir
Stevens, Raymond C.
Palczewski, Krzysztof
[J]. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2016, 55 (35) : 10331 - 10335
[4] Platelet Activation: The Mechanisms and Potential Biomarkers[J] . Seong-Hoon Yun,Eun-Hye Sim,Ri-Young Goh,Joo-In Park,Jin-Yeong Han,Michele Cea.BioMed Research International . 2016
[5] The platelet Fc receptor, FcγRIIa[J] . Jianlin Qiao,Mohammad Al‐Tamimi,Ross I. Baker,Robert K. Andrews,Elizabeth E. Gardiner.Immunol Rev . 2015 (1)
[6] A novel snake venom‐derived GPIb antagonist, anfibatide, protects mice from acute experimental ischaemic stroke and reperfusion injury[J] . Ting‐Ting Li,Man‐Li Fan,Shi‐Xiang Hou,Xiao‐Yi Li,Devin M Barry,Hui Jin,Sheng‐Yong Luo,Feng Kong,Lit‐Fui Lau,Xiang‐Rong Dai,Guo‐Hui Zhang,Lan‐Lan Zhou.British Journal of Pharmacology . 2015 (15)
[7] P2Y12 receptors: structure and function[J] . M. Cattaneo.J Thromb Haemost . 2015
[8] Thromboxane Prostaglandin Receptor Antagonist and Carotid Atherosclerosis Progression in Patients With Cerebrovascular Disease of Ischemic Origin: A Randomized Controlled Trial[J] . Michiel L. Bots,Ian Ford,Suzanne M. Lloyd,Stephane Laurent,Pierre J. Touboul,Michael G. Hennerici.Stroke . 2014 (8)
[9] Clopidogrel resistance: The way forward[J] . Shuvanan Ray.Indian Heart Journal . 2014
[10] Cangrelor: a new CHAMPION for percutaneous coronary intervention[J] . Shamir R Mehta.The Lancet . 2013 (9909)

← 1 2 →